Abbott to Unveil new ARCHITECT® ci4100™ Integrated Immunoassay and Clinical Chemistry System
Complete the form below to unlock access to ALL audio articles.
Abbott will preview the new ARCHITECT® ci4100™ Integrated System at the American Association of Clinical Chemistry (AACC) Annual Meeting this week.
The ci4100™ is an automated diagnostic analyzer that integrates immunoassay and clinical chemistry testing. Expected to be available in the United States by mid-2009, subject to regulatory approvals, the ci4100 will expand Abbott's family of integrated systems, offering low-volume-testing laboratories and clinics increased productivity and performance.
The ci4100 is designed to deliver improved productivity by providing a large capacity of up to 85 onboard reagents and 180 samples that can be continuously loaded and unloaded during the testing process.
The ci4100 also will integrate clinical chemistry and immunoassay testing with an expansive test menu, while maintaining consistent immediate turnaround times during both peak and off-peak hours. The ci4100 can generate up to 800 clinical chemistry and 100 immunoassay tests per hour, the company claims.
When available in the United States, the ci4100 will complete the ARCHITECT family of analyzers. The ARCHITECT system integrates two successful ARCHITECT instruments: the i1000SR immunoassay analyzer and the c4000 clinical chemistry system, which was developed with Abbott's partner, Toshiba.
Because the ci4100 is based on Abbott's existing ARCHITECT ci8200 and ci16200 integrated platforms, it shares common hardware, software and reagents. Upon regulatory approval, Abbott will be the only company offering high, medium and low-volume integrated solutions leveraging the same software, reagents and sample carriers, the company says.
